NYSE: TMOThermo Fisher Scientific Inc Stock
$426.17+7.47 (+1.78%)
Updated Jul 8, 2025
TMO Price
$426.17
Fair Value Price
N/A
Market Cap
$160.88B
52 Week Low
$385.46
52 Week High
$627.88
P/E
24.94x
P/B
3.26x
P/S
4.41x
PEG
1.33x
Dividend Yield
0.38%
Revenue
$42.90B
Earnings
$6.52B
Gross Margin
41.3%
Operating Margin
19.39%
Profit Margin
15.2%
Debt to Equity
1.01
Operating Cash Flow
$8B
Beta
0.86
Next Earnings
Jul 22, 2025
Ex-Dividend
Jun 13, 2025
Next Dividend
Jul 15, 2025
TMO Overview
Thermo Fisher Scientific Incorporated offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. Its products and services are sold through a direct sales force, customer-service professionals, e-commerce, third-party distributors, and catalogs. It has an alliance with the University of California. Thermo Fisher was incorporated in 1956 and is based in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TMO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TMO news, forecast changes, insider trades & much more!
TMO News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TMO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TMO ($426.17) is trading above its intrinsic value of $206.51, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TMO is good value based on its earnings relative to its share price (24.94x), compared to the US market average (30.75x)
P/E vs Market Valuation
TMO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more TMO due diligence checks available for Premium users.
Valuation
TMO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
24.94x
Industry
20.59x
Market
30.75x
TMO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TMO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TMO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.26x
Industry
3.62x
TMO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TMO price to earnings growth (PEG)
For valuing profitable companies with growth potential
TMO is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
TMO's financial health
Profit margin
Revenue
$10.4B
Net Income
$1.5B
Profit Margin
14.5%
TMO's Earnings (EBIT) of $8.32B... subscribe to Premium to read more.
Interest Coverage Financials
TMO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$99.0B
Liabilities
$49.7B
Debt to equity
1.01
TMO's short-term assets ($23.38B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TMO's long-term liabilities ($36.51B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TMO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TMO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$723.0M
Investing
-$527.0M
Financing
-$102.0M
TMO's operating cash flow ($8.14B)... subscribe to Premium to read more.
Debt Coverage Financials
TMO vs Diagnostic & Research Stocks
Thermo Fisher Scientific Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.